Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
AN2 Therapeutics, Inc. (ANTX) had Weighted-Average Shares Outstanding (Diluted) of 30.28M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-9.35M |
|
-- |
|
-- |
|
$10.04M |
|
$-10.04M |
|
$0.69M |
|
$-9.35M |
|
$-9.35M |
|
$-9.35M |
|
$-9.35M |
|
$-9.35M |
|
$-9.35M |
|
$-10.04M |
|
$-10.25M |
|
30.28M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
30.28M |
$-0.31 |
|
$-0.31 |
|
| Balance Sheet Financials | |
$64.02M |
|
-- |
|
$3.22M |
|
$67.23M |
|
$6.86M |
|
-- |
|
-- |
|
$6.86M |
|
$60.38M |
|
$60.38M |
|
$60.38M |
|
27.37M |
|
| Cash Flow Statement Financials | |
$-24.60M |
|
$21.14M |
|
$0.11M |
|
$21.35M |
|
$18.00M |
|
$-3.35M |
|
$4.85M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.33 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-24.60M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-15.49% |
|
-15.49% |
|
-13.91% |
|
-15.49% |
|
$2.21 |
|
$-0.81 |
|
$-0.81 |
|